{
    "symbol": "TGTX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-12 13:14:05",
    "content": " We are pleased to report that our burn for the third quarter of 2022 and under our previously guided range of $45 million to $50 million, landing at approximately $34 million for the quarter, also well below prior quarters, which as Mike said, is the result of our determined cost savings measured and our focused preparations for the upcoming launch of ublituximab, along with some timing differences, which we will incur in future quarters. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question."
}